Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Combining all-trans-retinoic acid, arsenic trioxide and idarubicin for the treatment of acute promyelocytic leukemia 

Combining all-trans-retinoic acid, arsenic trioxide and idarubicin for the treatment of acute promyelocytic leukemia 

Posted by on Jul 11, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of the combination of all-trans-retinoic acid (Vesanoid), arsenic trioxide (Trisenox), and idarubicin (Idamycin) as front-line treatment for acute promyelocytic leukemia.  This study concluded that this combination is safe and effective for these...

Read More

The impact of time to response to treatment on the outcomes of patients with accelerated-phase chronic myeloid leukemia

The impact of time to response to treatment on the outcomes of patients with accelerated-phase chronic myeloid leukemia

Posted by on Jul 11, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of time to response to treatment on the outcomes of patients with accelerated-phase chronic myeloid leukemia.  This study concluded that an early response to treatment is strongly associated with long-term survival in these patients.   Some background Tyrosine...

Read More

The impact of a pharmaceutical care program for patients with chronic lymphocytic leukemia treated with ibrutinib

The impact of a pharmaceutical care program for patients with chronic lymphocytic leukemia treated with ibrutinib

Posted by on Jul 5, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of a pharmaceutical care program on the safety and effectiveness of ibrutinib in patients with chronic lymphocytic leukemia. This study concluded that management of ibrutinib treatment by using a pharmaceutical care program results in improved survival and better...

Read More

Atrial fibrillation as a side effect of ibrutinib treatment in patients with chronic lymphocytic leukemia

Atrial fibrillation as a side effect of ibrutinib treatment in patients with chronic lymphocytic leukemia

Posted by on Jun 23, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the occurrence of atrial fibrillation (abnormal heart rhythm) in patients with chronic lymphocytic leukemia who are treated with ibrutinib.   This study concluded that atrial fibrillation does not require ibrutinib treatment to be stopped but is associated with worse outcomes for...

Read More

Cytarabine, aclarubicin and G-CSF as salvage treatment for hard to treat T cell acute lymphoblastic leukemia

Cytarabine, aclarubicin and G-CSF as salvage treatment for hard to treat T cell acute lymphoblastic leukemia

Posted by on Jun 23, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate cytarabine (Cytosar-U), aclarubicin (Aclacin) and G-CSF (Neupogen) as a salvage treatment for adult patients with relapsed or refractory T cell acute lymphoblastic leukemia.   This study concluded that this treatment combination is safe and effective as a salvage treatment...

Read More

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Posted by on Jun 21, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to compare outcomes of allogeneic hematopoietic stem cell transplant (alloHSCT) using cryopreserved (frozen) and fresh grafts in patients with blood cancers who received post-transplant cyclophosphamide (Cytoxan). This study concluded that cryopreservation (CP) does not affect the outcomes of HSCT in these patients....

Read More

Managing the side effects of ibrutinib treatment 

Managing the side effects of ibrutinib treatment 

Posted by on Jun 14, 2020 in Leukemia | 0 comments

In a nutshell This review aimed to discuss the toxicities of ibrutinib (Imbruvica) treatment and how to manage them. This review concluded that patients should be regularly monitored for toxicities and actively treated to reduce side effects and avoid disruption to treatment.  Some background Ibrutinib is a...

Read More